OncoSTRAT&GO

OncoSTRAT&GO allows to detect the tumor genomic heterogeneity through the simultaneous analysis of the solid biopsy and the liquid biopsy of the patient.

Along with the sequencing panel, a series of complementary and specific tests for each type of cancer are made, offering information about sensitivity or resistance to different types of chemotherapies or other drugs, which allows to personalize even more the treatment.

The study in solid biopsy analyzes by high throughput ultrasequencing the patient’s tumor through a panel that combines the analysis of the DNA and RNA of 209 genes that are involved in the cancer routes, which are target of approved or in development drugs, oncogenes, tumor suppressor genes, genes with copy number variations (CNV) and fusion genes.

So, besides to study the mutations in actionable genes offering new targeted and personalized treatments, it also helps to comprehend the underlying mechanisms of the tumor activation to provide with a complete picture of the patient’s disease.

The liquid biopsy study (blood) uses a new technology able to isolate the circulating tumor DNA (ctDNA) in blood to identify genomic alterations (mutations and CNV), allowing to measure and compare the tumor heterogeneity with the results obtained from the solid biopsy.  Besides, it can be used as reference (basal value) to later measure the disease evolution and response to the treatment through the OncoTRACE blood monitoring study.

OncoDEEPandTRACE

The OncoSTRAT&GO panel has been selected for its clinical and research applications:

  • It helps to identify each tumor unique characteristics to treat it accurately, detecting also the genomic tumor heterogeneity.
  • It increases treatment options for cancer patients.
  • It helps today’s treatments be more cost-effective and offers targeted therapies for patients.
  • It offers treatment possibilities to patients with unknown tumor origin.
  • It helps cut the costs and time of new drugs studies.
  • It helps obtain results adapted to the research project’s requirements.

 

The oncological report not only offers the ultrasequencing results, but interprets them by a bioinformatics and a clinical analysis.

The final result has the following contents:

  • Mutations present in the analyzed sequence of the tumor.
  • Association of the mutations with tumor development and progression.
  • Association of the mutations with specific treatments
  • Association of the mutations with clinical trials
  • Association of the result of IHC, FISH … with sensitivity or resistance to different types of chemotherapy or other drugs.

OncoSTRAT&GO has been designed to analyze all types of tumor samples.

The delivery time of this clinical service is 10-12 days (after receiving the sample and verifying its quality).

The results will be periodically discussed with a specialist team in order to acquire and improve knowledge about genomic tests.

The genomic analysis is done by OncoDNA (Belgium).

    1. The oncologist will be notified by email about when the report results will be ready, which can be downloaded from a document management platform.
    2. If the sample does not share any of the genes on the panel, there are other strategies which must be assessed by our team of specialists.

If you wish to receive more detailed information about OncoSTRAT&GO, please contact us by filling out this form or call on +34 961 829 423.

Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. F. Rothé, J.-F. Laes, D. Lambrechts, D. Smeets, D. Vincent, M. Maetens, D. Fumagalli, S. Michiels, S. Drisis, C. Moerman, J.-P. Detiffe, D. Larsimont, A. Awada, M. Piccart, C. Sotiriou and M. Ignatiadis.

Annals of Oncology 25.10 (2014): 1959-1965.